Founded in 1997, Chicago-based Integrated Genomics specializes in research in microbial genomics, biochemistry, and gene expression. Our scientists have broad experience in both in silico and wet lab sequencing, research and development with more than 100 relevant publications in these areas. Integrated Genomics has particularly long-standing relationships and active research in the area of lactic acid bacteria and pathogenic microbes, as well as a broad customer base across industry, academic and government institutions.Integrated Genomics’ products and services are based on ERGO™, our web-based genome analysis platform. ERGO™ integrates proprietary functional genomic data, metabolic reconstructions, expression profiling, and biochemical and microbiological data with publicly available information. Focused on microbial genomics, ERGO™ provides better and faster identification of gene function across all organisms.

Opko Health Inc. is a specialty healthcare company. The Company is focused on the discovery, development and commercialization of pharmaceuticals, drug delivery technologies, diagnostic systems, and instruments for the treatment, diagnosis and management of ophthalmic diseases and conditions. Its business consists of the development of ophthalmic pharmaceuticals and the development, commercialization and sale of ophthalmic diagnostic and imaging systems and instrumentation products. It focuses on exploring opportunities to acquire complementary pharmaceuticals, compounds, and technologies, which could, individually or in the aggregate, materially increase the scale of the Company’s business. On May 6, 2008, the Company completed the acquisition of Vidus Ocular, Inc. (Vidus).

Impax Laboratories, Inc. company was founded in 1993 and is headquartered in Hayward, California. mpax Laboratories, Inc. engages in the development and commercialization of bioequivalent and brand-name pharmaceuticals. It operates through two divisions, Global Pharmaceuticals and Impax Pharmaceutical. The Global Pharmaceuticals division develops, formulates, manufactures, and sells controlled release and specialty generic pharmaceutical products. This division offers generic prescription products directly to wholesalers and large retail drug chains; and generic over-the-counter and generic prescription products through unrelated third-party pharmaceutical entities. The Impax Pharmaceutical division develops proprietary brand pharmaceutical products that address central nervous system disorders, including Alzheimer's disease, attention deficit hyperactivity disorder, depression, epilepsy, migraines, multiple sclerosis, Parkinson's disease, and schizophrenia. As of March 10, 2009, the company marketed 70 generic pharmaceuticals representing dosage variations of 24 different pharmaceutical compounds through its Global Pharmaceuticals division, as well as 16 products representing dosage variations of 4 different pharmaceutical compounds through its alliance agreements partners. Impax Laboratories markets and sells its generic pharmaceutical prescription drug products in the continental United States of America and the Commonwealth of Puerto Rico. It has alliance agreements with Teva Pharmaceutical Industries, Ltd.; Wyeth; Schering-Plough Corporation; and DAVA Pharmaceuticals, Inc.

Novartis UK, pharmaceutical manufacturing isn't just a business, it's an art. Novartis UK is the British affiliate of Swiss-based Novartis AG, its operations include Novartis Pharmaceuticals UK, the prescription drug production arm that makes such products as tumor inhibitor Glivec and pain reliever Voltaren. Its Vaccine and Diagnostics division operates an influenza vaccine manufacturing facility. The company's Consumer Health division develops and manufactures such OTC products as Savlon antiseptic and Otrivin decongestant. Consumer Health also manufactures and markets drugs for companion animals and livestock, and includes contact lens maker CIBA Vision (UK).

Kyorin, founded in 1923, already has affiliates and subsidiaries in Germany and the US. KYORIN Co., Ltd. is a Japan-based holding company engaged in the manufacture and sale of pharmaceuticals. The Company operates in two business segments. The Pharmaceuticals segment is engaged in the manufacture, purchase and sale of pharmaceutical products, the evaluation of technologies, the inspection, analysis and negotiation of license affiliations, the manufacture of clinical testing products, as well as the research of new drugs and candidate compounds. The Others segment is involved in the development and sale of cosmetics, as well as raw materials of medicines and cosmetics, the promotion of sales, the planning and production of advertisements, the sale of packaging materials, in addition to the provision of advisory services and the operational management of funds.

NicOx S.A. company researches nitric oxide-donating drugs for the treatment of cardiovascular and metabolic ailments, inflammation, and pain. NicOx is researching the combination of nitric oxide with various compounds to treat a variety of diseases, including osteoarthritis, atherosclerosis (vascular inflammation), hypertension, ophthalmic conditions, and respiratory diseases. Its drug development efforts are partially conducted through co-development and licensing agreements with larger drug companies.

Paddock Laboratories, Inc. company was founded in 1977 by Chairman Bruce Paddock. Paddock Laboratories, Inc. company develops and manufactures bioequivalent generic pharmaceuticals and OTC specialty products. Paddock's product line includes suppositories, diabetes treatments, topical powders, enemas, injectables, and dermatological offerings, as well as compounding bases and charcoal products. Its manufacturing facilities are located in Minneapolis, Minnesota. In addition to the US market, some of Paddock's products are sold in Europe and the Asia/Pacific region through distributors.

Immunomedics, Inc. company was founded in 1982 and is headquartered in Morris Plains, New Jersey. Immunomedics, Inc. (Immunomedics) is a New Jersey-based biopharmaceutical company primarily focused on the development of monoclonal, antibody-based products for the targeted treatment of cancer, autoimmune and other serious diseases. The Company has developed a number of advanced technologies that allow it to create humanized antibodies that can be used either alone in unlabeled or naked form, or conjugated with radioactive isotopes, chemotherapeutics or toxins, in each case to create targeted agents. Immunomedics has licensed its product candidate epratuzumab, to UCB S.A. (UCB), for the treatment of all autoimmune disease indications worldwide. Epratuzumab’s most advanced clinical testing is for the treatment of systemic lupus erythematosus (SLE), and in non-Hodgkin’s lymphoma (NHL). The Company has antibody product candidates in clinical development targeting B-cell NHL, other B-cell mediated diseases and various solid tumors.

Pharsight wants to shorten the path to market for tomorrow's pharmaceutical breakthroughs. The company's software and consulting services aim to take some of the guesswork out of the drug development process for pharmaceutical and biotech firms, helping them choose the most promising drug candidates, to design effective clinical trials, and to keep up with regulatory reporting. Pharsight's WinNonlin and WinNonMix applications, for instance, analyze research and clinical data to help companies develop appropriate dosing regimens for clinical trials. And its consulting services help them make key strategy decisions about the future of development programs. Pharsight was acquired by Tripos in 2008.

Charles River Laboratories International, Inc. company was founded in 1947 and is headquartered in Wilmington, Massachusetts. Charles River Laboratories International, Inc. provides research models and laboratory animal support expertise to help its global partners advance their research and drug development efforts. The company offers a portfolio of services to support discovery and imaging, preclinical and early-phase clinical studies, and biopharmaceutical and endotoxin products and services for manufacturing and quality control. Its portfolio spans the entire research and drug development process, from IND consultation to discovery through market approval, allowing customized approaches to support both single-study or broad-based programs. Charles River Laboratories International serves pharmaceutical and biotechnology companies, as well as government agencies, hospitals, and academic institutions.

Inviting Real Estate Agents, Job Placements Agents, Educational Institutes, Software Service Providers, Real Estate Builders, Marriage Bureaus, Travel Agents, Restaurant Owners, Health & Fitness Centers and other Local Businesses to Post a FREE Classified Advertisement on Cootera.com Classifieds Website.